Inova’s Dr. Aragon-Ching Part of International Team Showing Benefit of Immunotherapy in Bladder Cancer Treatment

Jeanny B. Aragon-Ching, MD of the Inova Schar Cancer Institute has co-authored a groundbreaking bladder cancer research paper just published in the New England Journal of Medicine.

The large phase III clinical study showed that the addition of immunotherapy with Avelumab (Bavencio) increased the duration of overall survival by almost 50% in patients when given after chemotherapy in patients with locally advanced bladder cancer.

This practice-changing study showed how the addition of immunotherapy can have a dramatic impact on the lives of patients with certain cancers.

Read the article online: New England Journal of Medicine

Inova Newsroom

Share
Published by
Inova Newsroom

Recent Posts

Personalized mRNA treatment reduces melanoma recurrence in landmark Phase 3 trial

Inova Schar Cancer was among the trial’s leading-enrolling sites, with participation led by principal investigator…

2 weeks ago

Inova Loudoun Mobile Health Services: November 2026

Leesburg, VA – Inova Loudoun Hospital Mobile Health Services will be providing countywide blood pressure…

2 weeks ago

Inova Mount Vernon Hospital earns Magnet with Distinction®, ANCC’s highest honor for Nursing Excellence

Also recognized for 9 “Exemplars” for top performance Leaders and team members celebrate Inova Mount…

4 weeks ago

Inova Schar Cancer expands access to comprehensive cancer care with opening of Woodbridge location

New Prince William County location offers medical oncology, hematology, breast surgery, infusion and Inova Peterson…

4 weeks ago

Breast cancer screening and detection: 5 frequently asked questions

Kathleen Harden, MD is a breast oncology physician, board-certified in medical oncology and internal medicine…

4 weeks ago

Dru’s story: mapping out a great life with pulmonary fibrosis

Dru Smith, an interstitial lung disease patient, shares his experience and care journey. Reston resident…

1 month ago